ClinicalTrials.gg
CompletedNCT00337285Updated Aug 20, 2012Results posted

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

A Phase 3 interventional study of Vyvanse (lisdexamfetamine dimesylate), NRP104 in Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity and Attention Deficit Hyperactivity Disorders, sponsored by New River Pharmaceuticals. Completed at 45 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-08-20.

Sponsored by New River Pharmaceuticals (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
4th of 51
349 · median 48
Started
2006
with 2 others
Phase 3
15 of 51
none open now
Registered
4th of 51
by date
Lead sponsor
6 of 51
New River Pharmaceuticals

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 15 in phase 3, and was the 4th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.

Read the detailed description

This is a multi-center, open-label, and single-arm study to assess the safety of three NRP104 doses (30 mg, 50 mg, or 70 mg per day) for up to one (1) year in the treatment of adults with ADHD. Subjects who were randomized and met all inclusion/exclusion criteria in Protocol NRP104.303 are eligible for participation in this protocol. The study will consist of three periods: a screening/baseline period, a 4-week dose titration, and a long-term maintenance of up to 11 months. There are three possibilities for subjects that rollover from the NRP104.303 protocol. They are:

Subjects that rollover at the final visit of the NRP104.303 study (on the same day):

The screening and baseline procedures from this open label study will coincide with the final study visit of Protocol NRP104.303. Subject data from final study visit will be transferred and utilized for the open label study. On this same day, the subject will be consented for NRP104.304, inclusion/exclusion criteria will be assessed, the subject will be enrolled, and study medication will be dispensed.

Subjects that rollover not on the same day but within seven days of the NRP104.303 study:

If the subject returns to enroll into the NRP104.304 study within seven days of the final NRP104.303 study visit and has not taken any excluded medications for which a washout is required, the final study visit procedures and data from the NRP104.303 study will be transferred and utilized for the screening and baseline visit procedures of this study, where applicable. When the subject returns to the site, they will be consented, inclusion and exclusion criteria will be assessed, the subject will be enrolled, and study medication will be dispensed.

Subjects will require a full screening visit if more than 7 days have elapsed since they completed the NRP104.303 study:

After screening results have been received by the site, the site personnel will contact the subject via telephone to inform them of continued study eligibility. During this call the subject will be instructed to stop all medications for the treatment of ADHD, if any. This call starts the washout of all psychoactive medications, which should last 7 (±2) days. During the Washout Phone Contact, the visit dates for the Baseline visit (Visit 01) and Visits 02 through 05 should be scheduled at 7-day intervals as calculated from Baseline. After the washout is complete, subjects will return to the clinic for the baseline visit (Visit 01) to have the baseline procedures performed and to receive study medication.

Dose Titration

All subjects will initiate treatment at NRP104 30 mg for the 1st week. At the subsequent 4 weekly visits (Visits 02, 03, 04, and 05), the subject's daily dose of NRP104 may be increased or decreased by 20 mg at weekly intervals to achieve the optimal efficacy and tolerability, if deemed appropriate by the Investigator. In this study, the maximum daily dose of NRP104 that can be received by the subject is 70 mg, and the minimum daily dose of NRP104 the subject must take to continue the treatment is 30 mg.

Monthly Maintenance

At the end of the initial 4-week dose titration (Visit 05), subjects will enter the long-term maintenance of up to 11 months. Monthly visits, starting with Visit 06, will have a window of ±4 days. All visits will be scheduled relative to the Baseline Visit date. The last scheduled visit of the protocol is Visit 16 at Month 12. During the long-term maintenance, the subject's dose may be increased or decreased by 20 mg at any visit, if deemed appropriate by the Investigator, to maintain optimal treatment in terms of efficacy and tolerability. All reasons for dose changes should be well documented by the investigator during the maintenance period. Subjects who cannot maintain the minimum daily dose of NRP 30 mg due to intolerance will be withdrawn from the study.

Safety and Efficacy Assessments

ADHD Rating Scale (ADHD-RS) performed using adult prompts and Clinical Global Impression (CGI) will be assessed by the Investigator. The Pittsburgh Sleep Quality Index (PSQI) will be assessed once every three months following baseline.

Adverse events and concomitant medications will be recorded at each visit starting from the baseline visit. Vital signs will be measured at each visit from the screening visit. Physical exam and clinical laboratory tests (including pregnancy tests) will be assessed at Screening, Visit 10 and the final visit. Weight will be measured at the screening visit, baseline visit, and every month thereafter. Height will be measured at the screening visit and final visit. ECG parameters will be assessed at the screening visit, baseline visit, and every 3 months thereafter.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorders With Hyperactivity
  • Attention Deficit Hyperactivity Disorders

Keywords

  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Disorders with Hyperactivity
  • Attention Deficit Hyperactivity Disorders
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be 18-55 years of age, inclusive, at the time of consent of the NRP104.303 study.
  • Subject must have been randomized and must have met all inclusion/exclusion criteria in the NRP104.303 study.
  • Subject must be male or non-pregnant female. Females of (FOCP) must comply with restrictions noted in the protocol.
  • Subject must have a satisfactory medical assessment with no or relevant abnormalities as determined by medical history, PE, clinical and laboratory evaluation.
  • In the opinion of the investigator, the subject understands and is able, willing, and likely to fully comply with the study procedures and restrictions.
  • Subject must have given written, personally signed and dated to participate in the study in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines and applicable regulations before completing any study specific procedures.
  • Subject experienced no adverse events in a previous study of NRP104 or elsewhere that would preclude continued exposure to NRP104.

Exclusion criteria

Exclusion Criteria:

  • Subject has any concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol. Subjects who have a history of mental retardation or a severe learning disability are excluded.
  • Subject has a known cardiac structural abnormality or any other condition that may affect cardiac performance.
  • Subject has any or laboratory abnormality known to the investigator prior to dispensation of study medication.
  • Subject has a resting sitting systolic blood pressure or diastolic blood pressure deemed clinically significant by the investigator.
  • Subject has used any prohibited prescription medication except for medications used to treat ADHD within 30 days of screening visit. Hormonal are acceptable.
  • Subject has a positive urine drug result at Screening (with the exception of subject's current stimulant therapy, if any).
  • Subject has taken an drug or taken part in a clinical trial within 30 days prior to Screening (except for participating in an NRP104 study).
  • The female subject is pregnant or lactating.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
349 participants (actual)

Study arms

  • Experimental
    1

    Drug: Vyvanse (lisdexamfetamine dimesylate), NRP104

Interventions

06

What researchers measure

Primary outcomes

  1. Change in ADHD-RS-IV Total Score From Baseline at Up to One Year

    Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: up to one year

Secondary outcomes

  1. Number of Participants With Improvement on CGI-I

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes 1 and 2 on the scale.

    Time frame: Up to 1 year

  2. Change in PSQI Total Score From Baseline at Up to One Year

    Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire consisting of 18 items which generates seven component scores on a scale from 0 (better sleep) to 3 (worse sleep) resulting in a global score of 0-21, where a higher number reflects worse sleep quality.

    Time frame: up to 1 year

07

Results

Posted Jul 17, 2009

Participant flow

Participant flow — Overall Study
MilestoneVyvanse
Started349
Completed191
Not completed158
Withdrew: Withdrawal by subject42
Withdrew: Lost to follow-up41
Withdrew: Adverse event28
Withdrew: Protocol violation27
Withdrew: Lack of efficacy11
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Lack of protocol compliance7

Outcome measures

PrimaryChange in ADHD-RS-IV Total Score From Baseline at Up to One Year

Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
up to one year
Reported as:
Mean · Units on a scale
Change in ADHD-RS-IV Total Score From Baseline at Up to One Year
Units on a scaleVyvanse
Change in ADHD-RS-IV Total Score From Baseline at Up to One Year-24.8 ± 11.7
Statistical analysis
  • Vyvanse · t-test, 2 sided · p = < 0.0001
SecondaryNumber of Participants With Improvement on CGI-I

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes 1 and 2 on the scale.

Time frame:
Up to 1 year
Reported as:
Number · Participants
Number of Participants With Improvement on CGI-I
ParticipantsVyvanse
Number of Participants With Improvement on CGI-I290
SecondaryChange in PSQI Total Score From Baseline at Up to One Year

Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire consisting of 18 items which generates seven component scores on a scale from 0 (better sleep) to 3 (worse sleep) resulting in a global score of 0-21, where a higher number reflects worse sleep quality.

Time frame:
up to 1 year
Reported as:
Mean · Units on a scale
Change in PSQI Total Score From Baseline at Up to One Year
Units on a scaleVyvanse
Change in PSQI Total Score From Baseline at Up to One Year-1.3 ± 2.8
Statistical analysis
  • Vyvanse · t-test, 2 sided · p = < 0.0001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vyvanse———
Most frequent serious events
Most frequent serious events
EventVyvanse
Chest painMusculoskeletal and connective tissue disorders1/349
Anal fissureGastrointestinal disorders1/349
Cocaine and alcohol toxicitySocial circumstances1/349
SarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/349
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/349
Foot fractureInjury, poisoning and procedural complications1/349
Cholecystitis acuteHepatobiliary disorders1/349
Arthritis bacterialInfections and infestations1/349
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVyvanse
Upper respiratory tract infectionInfections and infestations76/349
InsomniaPsychiatric disorders68/349
HeadacheNervous system disorders60/349
Dry mouthGastrointestinal disorders58/349
Decreased appetiteMetabolism and nutrition disorders50/349
IrritabilityGeneral disorders39/349
AnxietyPsychiatric disorders29/349
NasopharyngitisInfections and infestations26/349
SinusitisInfections and infestations23/349
Weight decreasedInvestigations21/349

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Vyvanse
<=18 years0
Between 18 and 65 years349
>=65 years0
Age Continuous
Age Continuous(years)Vyvanse
Mean35.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Vyvanse
Female159
Male190
Region of Enrollment
Region of Enrollment(participants)Vyvanse
United States349
08

Study locations

45 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Research, Inc.
    El Centro, California 92243, United States
  • University of California, Irvine Child Development Center
    Irvine, California 92612, United States
  • Bay Area Research Institute
    LaFayette, California 94549, United States
  • Peninsula Research Associates
    Rolling Hills Estate, California 90274, United States
  • University of California, San Francisco, Dept. of Psychiatry
    San Francisco, California 94143, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80304, United States
  • Psychiatric Medicine Center
    New London, Connecticut 06320, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Miami Research Associates
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Janus Center for Psychiatric Research LLC
    West Palm Beach, Florida 33407, United States
  • Northwest Behavioral Research Center
    Roswell, Georgia 30076, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Johns Hopkins at Green Spring Station
    Lutherville, Maryland 21093, United States
  • Marc Hertzman, MD
    Rockville, Maryland 20852, United States
  • Masschusetts General Hospital
    Cambridge, Massachusetts 02138, United States
  • Summit Research Network (Michigan) Inc.
    Flint, Michigan 48507, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • St Charles Psychiatric Associates-Midwest Research
    St Charles, Missouri 63301, United States
  • Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada 89128, United States
  • CNS Research Institute (CRI)
    Clementon, New Jersey 08021, United States
  • VA New York Harbor Healthcare System
    New York, New York 10010, United States
  • Duke University ADHD Program
    Durham, North Carolina 27705, United States
  • Richard Weisler and Associates
    Raleigh, North Carolina 27609, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon 97210-2659, United States
  • CNS Research Institute, P.C.
    Philadelphia, Pennsylvania 19149, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • Claghorn-Lesem Research Clinic
    Bellaire, Texas 77401, United States
  • Bayou City Research
    Houston, Texas 77007, United States
  • Red Oak Psychiatry Associates, P.A.
    Houston, Texas 77090, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
  • John M. Turnbow, MD, PA
    Lubbock, Texas 79423, United States
  • The Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Psychiatric Alliance of the Blue Ridge Clinical Research
    Charlottesville, Virginia 22903, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Brighton Research Group
    Virginia Beach, Virginia 23452, United States
  • Summit Research Network LLC (Seattle)
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Ginsberg L, Katic A, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Adler LA. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Curr Med Res Opin. 2011 Jun;27(6):1097-107. doi: 10.1185/03007995.2011.567256. Epub 2011 Mar 28. PubMed 21438796 ↗
  • Mattingly G, Weisler R, Dirks B, Babcock T, Adeyi B, Scheckner B, Lasser R. Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. Innov Clin Neurosci. 2012 May;9(5-6):22-30. PubMed 22808446 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Nov 2007 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2006
First posted
Jun 15, 2006
Start
Jul 2006
Primary completionActual
Nov 2007
CompletionActual
Jun 2008
Results first posted
Jul 17, 2009
Last update
Aug 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00337285
Collaborators
Shire
First posted
Jun 15, 2006
Start date
Jul 2006
Primary completion
Nov 2007
Completion
Jun 2008
Results posted
Jul 17, 2009
Last update
Aug 20, 2012

Study contacts

Joseph Biederman, M.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion